Infection control in cystic fibrosis: Barriers to implementation and ideas for improvement

Current Opinion in Pulmonary Medicine

Volumn 15, Issue 6, 2009, Pages 626-631

  Saiman, Lisa ^a   Garber, Elizabeth ^a  

^a Howard Hughes Medical Institute   (United States)

Author keywords

Adherence; Barriers; Infection control

Indexed keywords

AGAR MEDIUM; BURKHOLDERIA CEPACIA; CYSTIC FIBROSIS; GRAM NEGATIVE BACTERIUM; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH SURVEY; HOSPITAL PATIENT; HUMAN; INFECTION CONTROL; LABORATORY TEST; MICROBIOLOGY; OUTPATIENT; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS; UNITED STATES;

AMBULATORY CARE; BACTERIAL INFECTIONS; CYSTIC FIBROSIS; GUIDELINE ADHERENCE; HUMANS; INFECTION CONTROL; ORGANIZATIONAL POLICY; PATIENT SAFETY; PRACTICE GUIDELINES AS TOPIC; QUALITY IMPROVEMENT; UNITED STATES;

EID: 70349829632     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328330d974     Document Type: Review

References (27)

1. Saiman L, Siegel J, Cystic Fibrosis F. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect Control Hosp Epidemiol 2003; 24:S6-S52. (Pubitemid 36617275)
2. Biddick R, Spilker T, Martin A, LiPuma JJ. Evidence of transmission of Burkholderia cepacia, Burkholderia multivorans and Burkholderia dolosa among persons with cystic fibrosis. FEMS Microbiol Lett 2003; 228: 57-62.
3. O'Carroll MR, Syrmis MW, Wainwright CE, et al. Clonal strains of Pseudomonas aeruginosa in paediatric and adult cystic fibrosis units. Eur Respir J 2004; 24:101-106.
4. Edenborough FP, Stone HR, Kelly SJ, et al. Genotyping of Pseudomonas aeruginosa in cystic fibrosis suggests need for segregation. J Cyst Fibros 2004; 3:37-44.
5. Stone A, Quittell L, Zhou J, et al. Staphylococcus aureus nasal colonization among pediatric cystic fibrosis patients and their household members. Pediatr Infect Dis J (in press).
6. Van Daele S, Verhelst R, Claeys G, et al. Shared genotypes of Achromobacter xylosoxidans strains isolated from patients at a cystic fibrosis rehabilitation center. J Clin Microbiol 2005; 43:2998-3002.
7. Ronne Hansen C, Pressler T, Hoiby N, Gormsen M. Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients; a retrospective case control study. J Cyst Fibros 2006; 5:245-251.
8. Zhou J, Garber E, Desai M, Saiman L. Compliance of clinical microbiology laboratories in the United States with current recommendations for processing respiratory tract specimens from patients with cystic fibrosis. J Clin Microbiol 2006; 44:1547-1549.
9. Garber E, Desai M, Zhou J, et al. Barriers to adherence to cystic fibrosis infection control guidelines. Pediatr Pulmonol 2008; 43:900-907.
10. Elborn JS, Hodson M, Bertram C. Implementation of European standards of care for cystic fibrosis: control and treatment of infection. J Cyst Fibros 2009; 8:211-217.
11. Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities. MMWR 1994, 43:1-132.
12. Zhou J, Garber E, Saiman L. Survey of infection control policies for patients with cystic fibrosis in the United States. Am J Infect Control 2008; 36:220-222.
13. Cabana MD, Ebel BE, Cooper-Patrick L, et al. Barriers pediatricians face when using asthma practice guidelines. Arch Pediatr Adolesc Med 2000; 154:685-693.
14. Cabana MD, Rand CS, Becher OJ, Rubin HR. Reasons for pediatrician nonadherence to asthma guidelines. Arch Pediatr Adolesc Med 2001; 155:1057-1062.
15. Ullrich G, Wiedau S, Schulz W, Steinkamp G. Parental knowledge and behaviour to prevent environmental P. aeruginosa acquisition in their children with CF. J Cyst Fibros 2008; 7:231-237.
16. Blau H, Mussaffi H, Zahav MM, et al. Microbial contamination of nebulizers in the home treatment of cystic fibrosis. Child Care Health Dev 2006; 33:491-495.
17. O'Malley CA. Infection control in cystic fibrosis: cohorting, cross-contamination, and the respiratory therapist. Respir Care 2009; 54:641-657.
18. Geddes D. Segregation is not good for patients with cystic fibrosis. J R Soc Med 2008; 101:S36-S38.
19. Zuckerman JB, Zuaro DE, Prato BS, et al. Bacterial contamination of cystic fibrosis clinics. J Cyst Fibros 2009; 8:186-192.
20. Festini F, Taccetti G, Mannini C, et al. Patient risk of contact with respiratory pathogens from inanimate surfaces in a cystic fibrosis outpatient clinic. A prospectivestudyoverafour-yearperiod.Pediatr Pulmonol 2007;42:779-784.
21. Conway S. Segregation is good for patients with cystic fibrosis. J R Soc Med 2008; 101:S31-S35.
22. Armstrong DS, Nixon GM, Carzino R, et al. Detection of a widespread clone of Pseudomonas aeruginosa in a pediatric cystic fibrosis clinic. Am J Respir Crit Care Med 2002; 166:983-987.
23. Razvi S, Quittell L, Sewall A, et al. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995-2005. Chest 2009 [Epub ahead of print]. doi: 10.1378/chest.09-0132.
24. Duff AJA. Psychological consequences of segregation resulting from chronic Burkholderia cepacia infection in adults with CF. Thorax 2002; 57:756-758.
25. Harrop M. Psychosocial impact of cystic fibrosis in adolescence. Paediatr Nurs 2007; 19:41-45.
26. Griffiths AL, Armstrong D, Carzino R, Robinson P. Cystic fibrosis patients and families support cross-infection measures. Eur Respir J 2004; 24:449-452.
27. Russo K, Donnelly M, Reid AJ. Segregation: the perspectives of young patients and their parents. J Cyst Fibros 2006; 5:93-99.